SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRVT Miravant Med Tech: Infinity and Beyond? -- Ignore unavailable to you. Want to Upgrade?


To: Ian@SI who wrote (66)1/24/2002 12:27:30 PM
From: Marty Rubin  Respond to of 67
 
Cyberonics (CYBX) trial received "insufficient stimulation," not MRVT. My mistake.

At anyrate, I was not counting on SnET2, but on other promising drugs it has in its pipeline that will encourage new funding by its largest shareholder (Pharmacia).